ACR Image Metrix Formalizes Imaging Biomarker Development Program
ACR Image Metrix has formalized a biomarker and imaging development program.
ACR Image Metrix has partnered with radiopharmacies to overcome the challenging logistics of using radiolabeled tracers as biomarkers in clinical research and has formalized a biomarker imaging development program that includes clinical strategy, trial design and execution.
“ACR Image Metrix has experience and understands the challenges with biomarkers,” stated Michael J. Morales, General Manager. “Our operational expertise and infrastructure ensure our clients’ data meet regulatory requirements. Additionally, we are currently assisting several sponsors with their biomarker clinical development programs in multiple therapeutic categories. This is a new area for sponsors as well as the FDA, and ACR Image Metrix aims to add value to this new frontier in drug development.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
